B

Chieh-Lung Cheng1, Tai-Chung Huang2, Yu-Hsuan Tuan2

  • 1Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.

概括

在R-CHOP后进展的时间是扩散性大B细胞淋巴瘤患者复发或耐药疾病的关键预测因素. 进展时间较短表明预后较差,需要新的治疗方法.